• Member Statistics

    • 786,956 Colleagues-to-Date [Sponsored by a generous R&D grant from iMBA, Inc.]
  • David E. Marcinko [Editor-in-Chief]

    As a former Dean and appointed Distinguished University Professor and Endowed Department Chair, Dr. David Edward Marcinko MBA was a NYSE broker and investment banker for a decade who was respected for his unique perspectives, balanced contrarian thinking and measured judgment to influence key decision makers in strategic education, health economics, finance, investing and public policy management.

    Dr. Marcinko is originally from Loyola University MD, Temple University in Philadelphia and the Milton S. Hershey Medical Center in PA; as well as Oglethorpe University and Emory University in Georgia, the Atlanta Hospital & Medical Center; Kellogg-Keller Graduate School of Business and Management in Chicago, and the Aachen City University Hospital, Koln-Germany. He became one of the most innovative global thought leaders in medical business entrepreneurship today by leveraging and adding value with strategies to grow revenues and EBITDA while reducing non-essential expenditures and improving dated operational in-efficiencies.

    Professor David Marcinko was a board certified surgical fellow, hospital medical staff President, public and population health advocate, and Chief Executive & Education Officer with more than 425 published papers; 5,150 op-ed pieces and over 135+ domestic / international presentations to his credit; including the top ten [10] biggest drug, DME and pharmaceutical companies and financial services firms in the nation. He is also a best-selling Amazon author with 30 published academic text books in four languages [National Institute of Health, Library of Congress and Library of Medicine].

    Dr. David E. Marcinko is past Editor-in-Chief of the prestigious “Journal of Health Care Finance”, and a former Certified Financial Planner® who was named “Health Economist of the Year” in 2010. He is a Federal and State court approved expert witness featured in hundreds of peer reviewed medical, business, economics trade journals and publications [AMA, ADA, APMA, AAOS, Physicians Practice, Investment Advisor, Physician’s Money Digest and MD News] etc.

    Later, Dr. Marcinko was a vital recruited BOD member of several innovative companies like Physicians Nexus, First Global Financial Advisors and the Physician Services Group Inc; as well as mentor and coach for Deloitte-Touche and other start-up firms in Silicon Valley, CA.

    As a state licensed life, P&C and health insurance agent; and dual SEC registered investment advisor and representative, Marcinko was Founding Dean of the fiduciary and niche focused CERTIFIED MEDICAL PLANNER® chartered professional designation education program; as well as Chief Editor of the three print format HEALTH DICTIONARY SERIES® and online Wiki Project.

    Dr. David E. Marcinko’s professional memberships included: ASHE, AHIMA, ACHE, ACME, ACPE, MGMA, FMMA, FPA and HIMSS. He was a MSFT Beta tester, Google Scholar, “H” Index favorite and one of LinkedIn’s “Top Cited Voices”.

    Marcinko is “ex-officio” and R&D Scholar-on-Sabbatical for iMBA, Inc. who was recently appointed to the MedBlob® [military encrypted medical data warehouse and health information exchange] Advisory Board.

    entrepreneur

    Frontal_lobe_animation

  • ME-P Information & Content Channels

  • ME-P Archives Silo [2006 – 2020]

  • Ann Miller RN MHA [Managing Editor]

    ME-P SYNDICATIONS:
    WSJ.com,
    CNN.com,
    Forbes.com,
    WashingtonPost.com,
    BusinessWeek.com,
    USNews.com, Reuters.com,
    TimeWarnerCable.com,
    e-How.com,
    News Alloy.com,
    and Congress.org

    Comprehensive Financial Planning Strategies for Doctors and Advisors: Best Practices from Leading Consultants and Certified Medical Planners(TM)

    Product Details

    Product Details

    Product Details

  • CERTIFIED MEDICAL PLANNER® program

    New "Self-Directed" Study Option SinceJanuary 1st, 2018
  • Most Recent ME-Ps

  • PodiatryPrep.org


    BOARD CERTIFICATION EXAM STUDY GUIDES
    Lower Extremity Trauma
    [Click on Image to Enlarge]

  • ME-P Free Advertising Consultation

    The “Medical Executive-Post” is about connecting doctors, health care executives and modern consulting advisors. It’s about free-enterprise, business, practice, policy, personal financial planning and wealth building capitalism. We have an attitude that’s independent, outspoken, intelligent and so Next-Gen; often edgy, usually controversial. And, our consultants “got fly”, just like U. Read it! Write it! Post it! “Medical Executive-Post”. Call or email us for your FREE advertising and sales consultation TODAY [770.448.0769]

    Product Details

    Product Details

  • Medical & Surgical e-Consent Forms

    ePodiatryConsentForms.com
  • iMBA R&D Services

    Commission a Subject Matter Expert Report [$250-$999]January 1st, 2019
    Medical Clinic Valuations * Endowment Fund Management * Health Capital Formation * Investment Policy Statement Analysis * Provider Contracting & Negotiations * Marketplace Competition * Revenue Cycle Enhancements; and more! HEALTHCARE FINANCIAL INDUSTRIAL COMPLEX
  • iMBA Inc., OFFICES

    Suite #5901 Wilbanks Drive, Norcross, Georgia, 30092 USA [1.770.448.0769]. Our location is real and we are now virtually enabled to assist new long distance clients and out-of-town colleagues.

  • ME-P Publishing

  • SEEKING INDUSTRY INFO PARTNERS?

    If you want the opportunity to work with leading health care industry insiders, innovators and watchers, the “ME-P” may be right for you? We are unbiased and operate at the nexus of theoretical and applied R&D. Collaborate with us and you’ll put your brand in front of a smart & tightly focused demographic; one at the forefront of our emerging healthcare free marketplace of informed and professional “movers and shakers.” Our Ad Rate Card is available upon request [770-448-0769].

  • Reader Comments, Quips, Opinions, News & Updates

  • Start-Up Advice for Businesses, DRs and Entrepreneurs

    ImageProxy “Providing Management, Financial and Business Solutions for Modernity”
  • Up-Trending ME-Ps

  • Capitalism and Free Enterprise Advocacy

    Whether you’re a mature CXO, physician or start-up entrepreneur in need of management, financial, HR or business planning information on free markets and competition, the "Medical Executive-Post” is the online place to meet for Capitalism 2.0 collaboration. Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds. ******************************************************************** THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
  • OIG Fraud Warnings

    Beware of health insurance marketplace scams OIG's Most Wanted Fugitives at oig.hhs.gov

Bank Deals Similar to Goldman Sach’s Gone Awry

Other Major Banks Participated, Too?

By Marian Wang, ProPublica – April 16, 2010 1:36 pm EDT

As you may have heard, or read on this ME-P, Goldman Sachs is being sued for fraud [1] by the Securities and Exchange Commission [2] for allegedly misleading investors about a deal that Goldman helped structure and sell. In the civil suit, the SEC specifically faulted Goldman for failing to disclose that a hedge fund was helping create the investment while betting big the deal would fail.

According to the SEC, Goldman Sachs knew about the hedge fund’s bets, knew it played a significant role in choosing the assets in the portfolio, and yet did not tell investors about it. (Goldman Sachs has called the SEC’s accusations “completely unfounded in law and fact.” And in another more detailed statement [3], it said it “did not structure a portfolio that was designed to lose money.”) 

[picapp align=”none” wrap=”false” link=”term=Goldman+Sachs&iid=8541566″ src=”0/4/f/8/The_Goldman_Sachs_7d6f.jpg?adImageId=12513388&imageId=8541566″ width=”380″ height=”568″ /]

In ProPublica

As we reported at ProPublica last week, many other major investment banks were doing a similar thing [4].

Investment banks including JPMorgan Chase [5], Merrill Lynch [6] (now part of Bank of America), Citigroup, Deutsche Bank and UBS also created CDOs that a hedge fund named Magnetar was both helping create and betting would fail. Those investment banks marketed and sold the CDOs to investors without disclosing Magnetar’s role or the hedge fund’s interests.

Here is a list of the banks that were involved [7] in Magnetar deals, along with links to many of the prospectuses on the deals, which skip over Magnetar’s role. In all, investment banks created at least 30 CDOs with Magnetar, worth roughly $40 billion overall. Goldman’s 25 Abacus CDOs — one of which is the basis of the SEC’s lawsuit — amounted to $10.9 billion [8].

One reporter Jake Bernstein explained the investment banks’ disclosure failures on Chicago Public Radio’s This American Life [9]:

On the Magnetar Hedge Fund

The role of Magnetar, both as equity investor and in their bets against the very CDOs they helped create were not disclosed in any way to investors in the written documents about the deals. Not the marketing materials, not the prospectuses, not in the hundreds of pages that an investor could get to see information about the deal was it disclosed that it was in fact Magnetar who’d helped create the deal, and who’d bet against.

That is, of course, along the lines of what the SEC is suing Goldman Sachs for now. The SEC’s suit also says CDOs like the ones Goldman built “contributed to the recent financial crisis by magnifying losses associated with the downturn in the United States housing market.”

Notably, the SEC did not sue the hedge fund [10] involved in Goldman’s Abacus deals — Paulson & Co. — or its manager, John Paulson. Instead, it’s going after Goldman. And as we pointed out in our reporting, there’s no evidence that what Magentar did was illegal [11].

Assessment

We’ve called the major banks involved in Magnetar CDO deals to see if they were concerned about similar lawsuits. Thus far, Bank of America, Citigroup, Deutsche, Wells Fargo (which bought Wachovia) and UBS have responded and have all declined our requests for comment. Here is Magnetar’s response [12] to our original reporting.

Conclusion

And so, your thoughts and comments on this ME-P are appreciated. Who else can send us some insider-knowledge on this sordid topic? Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, be sure to subscribe. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Get our Widget: Get this widget!

Our Other Print Books and Related Information Sources:

Practice Management: http://www.springerpub.com/prod.aspx?prod_id=23759

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Healthcare Organizations: www.HealthcareFinancials.com

Health Administration Terms: www.HealthDictionarySeries.com

Physician Advisors: www.CertifiedMedicalPlanner.com

Subscribe Now: Did you like this Medical Executive-Post, or find it helpful, interesting and informative? Want to get the latest ME-Ps delivered to your email box each morning? Just subscribe using the link below. You can unsubscribe at any time. Security is assured.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

10 Responses

  1. Oh No … Not Others Too?

    Accusations that venerated investment bankers at Goldman Sachs defrauded customers who bought risky subprime mortgages have only just begun to reverberate through the financial world.

    http://www.msnbc.msn.com/id/36616548/ns/business-the_new_york_times

    Now are other banks implicated, too?

    Chase

    Like

  2. Warren Buffett Takes $1 Billion Hit As SEC Charges Goldman Sachs

    He can’t be happy now that the SEC is charging Goldman with fraud.

    http://www.cnbc.com//id/36607263

    D-Oh!
    Jane

    Like

  3. Charges Aside – What About Goldman’s Nondisclosure of a Potential Lawsuit?

    In a recent conference call, Goldman Sachs’ co-general counsel Greg Palm said the firm was “somewhat surprised” by the SEC’s civil suit last week, since “no one had told us in advance.”

    Typically, when the SEC files a lawsuit, it gives companies advance notice, so they can either settle the case quickly or brace themselves for a PR hit. In this case, the SEC didn’t give Goldman the courtesy.

    Link: http://www.propublica.org/ion/blog/item/charges-aside-was-goldmans-non-disclosure-of-potential-lawsuit-material

    Source: ProPublica

    Like

  4. Sar-Box and Warren Buffet

    We usually don’t associate Warren Buffet with whistleblowers, in part because we assume the Oracle of Omaha’s integrity extends across his empire.

    But, he has unfortunately just been embroiled in another saga that features a former executive at Forest River, an RV manufacturer that was bought by Berkshire Hathaway for $800 million, who fancies himself a whistleblower.

    http://www.businessweek.com/news/2010-04-08/berkshire-ex-manager-claims-he-lost-job-for-reporting-fraud.html

    Poor Warren has been taking the hits recently, hasn’t he!

    Henry

    Like

  5. Goldman Sachs Points to Magnetar Trades in Its Defense
    by Marian Wang, ProPublica – April 19, 2010 4:16 pm EDT

    Follow-up

    Last week, when news broke of the SEC’s lawsuit against Goldman Sachs—in which the bank was accused of failing disclose to investors that a hedge fund had helped stock a Goldman CDO and then bet against it—we pointed out that what Goldman did is quite similar to what other major investment banks seem to have done [1] with the hedge fund Magnetar. (Goldman denies [2] that its investments were built to fail. Magnetar also denies [3] it was betting against CDOs it helped create.)

    As it turns out, Goldman Sachs itself beat us to pointing out those similarities.
    In documents [4] Goldman submitted [5] to the SEC in September 2009, after the regulator officially notified Goldman of possible civil charges, the investment bank argued that other investment banks also hadn’t fully disclosed [5] to CDO investors the involvement of third-party hedge funds, namely Magnetar.

    In a section entitled, “Market Practice Did Not Entail Disclosure of a Short Investor’s Participation,” Goldman pinpointed non-disclosure by other investment banks [5] in several Magnetar CDO deals, including Auriga and Norma.

    Here’s what Goldman wrote about Merrill’s disclosures in the Auriga deal:

    Goldman Sachs understands that the Initial Preferred Securityholder was Magnetar Capital LLC (“Magnetar”), but this information is not disclosed in the offering circular. Goldman Sachs does not know the extent to which Magnetar played a role in the selection of the Auriga portfolio, and this too is not disclosed in the offering circular. In fact, other than listing 18 pages of “eligibility criteria” (id. at 143-161), which state in general terms what the portfolio may contain, the Auriga offering circular does not mention the contents of the portfolio at all.

    Goldman also made the same point about Merrill’s failure to disclose Magnetar’s role in creating Norma, a deal we’ve written about [6]. (The Wall Street Journal also had a detailed piece [7] on Norma, in 2007.) From Goldman’s letter to the SEC:

    The Norma CDO, which also was an actively managed transaction underwritten by Merrill Lynch & Co., contained disclosures that were materially similar to those used in Auriga. (Norma Offering Circular at 56, 67.) We understand that Magnetar was the “Initial Preference Shareholder”6 for the Norma transaction, but this information is not disclosed in the offering circular. Similarly, we do not know whether Magnetar played a role in the selection of the Norma portfolio, and this too is not disclosed in the offering circular.

    Goldman has consistently maintained that not disclosing a hedge fund’s bets against a CDO was “normal business practice [2],” and has cited other examples of nondisclosure to buttress its point. It remains to be seen whether this defense will work—or whether the SEC will simply go after the others as well.

    Source: http://www.propublica.org/ion/blog/item/sec-rebuked-for-regulatory-failure-with-lehman-brothers
    Source: http://www.propublica.org/ion/podcast/item/bernstein-and-eisinger-on-the-magnetar-trade

    Like

  6. Crucial investor not targeted in Goldman suit

    http://www.msnbc.msn.com/id/36612092/ns/business-the_new_york_times

    John Paulson is in the spotlight after making billions betting on subprime products.

    John

    Like

  7. Did you know that the CEO of Goldman Sachs and other executives from several Wall Street powerhouses will be coming before Congress 10 days after the government accused the firm of fraud?

    http://www.msnbc.msn.com/id/36795143/ns/business-us_business

    But … is this too little … too late?

    Jack

    Like

  8. Did you here about Goodman-Sachs?

    Goldman shares plunge this weekend on gossip of a possible criminal probe.

    http://www.msnbc.msn.com/id/36861208/ns/business-us_business

    The brokerage, already facing civil charges, could also face criminal counts.
    Well, what do you think about that?

    Samantha

    Like

  9. Of Course … He Does

    Warren Buffett just launched a forceful defense of Berkshire Hathaway Inc’s $5 billion investment in Goldman Sachs Group Inc and the investment bank’s embattled chief executive, Lloyd Blankfein.

    http://www.msnbc.msn.com/id/36888741/ns/business

    Kentwick

    Like

  10. A Federal Regulator Is Probing Wells Fargo’s Mortgage Practices

    A consumer watchdog agency is following up on ProPublica’s reports that the scandal-ridden bank improperly charged fees to customers from Los Angeles to Oregon. Meanwhile, the bank is conducting its own inquiry.

    http://go.propublica.org/e/125411/l-utm-campaign-dailynewsletter/43vcfn/131548095

    Geno

    Like

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: